Manganese dipyridoxyl-diphosphate (MnDPDP) as a viability marker in patients with myocardial infarction.
OBJECTIVE
To evaluate contrast accumulation in left ventricular (LV) myocardium after manganese dipyridoxyl-diphosphate (MnDPDP) administration in patients with recent first time myocardial infarction.


METHODS
MnDPDP (5 micromol/kg) was administered to 10 patients with recent myocardial infarction (three to 12 weeks). One slice of interest (SOI) likely to traverse the infarction was chosen, and sectorial pre- and postcontrast longitudinal relaxivity rates (R(1)) and signal changes during infusion were estimated with a fast gradient echo sequence. LV volume and wall thickening were measured in short-axis cine recordings. Infarct localization from R(1) and wall thickening data were compared by vector analyses.


RESULTS
Reduced wall thickening was associated with reduced precontrast R(1) and reduced contrast enhancement. Both remote and infarcted regions showed rapid initial contrast accumulation. In remote regions, this was followed by a continuing slow increase. Mean precontrast R(1) was 0.87 +/- 0.06 second(-1) in infarcted regions and 0.96 +/- 0.03 second(-1) in remote regions (P < 0.001). Mean R(1) change over one hour was 0.24 +/- 0.07 second(-1) in infarcted regions and 0.38 +/- 0.03 second(-1) in remote regions (P < 0.0001).


CONCLUSIONS
Remote regions showed larger increases in R(1) than infarcted regions. This is most likely due to selective and slow Mn accumulation in viable myocytes.
Skjold
Arne
A
Department of Circulation and Medical Imaging (ISB), Faculty of Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway. Arne.Skjold@stolav.no
Amundsen
Brage H
BH
Wiseth
Rune
R
Støylen
Asbjørn
A
Haraldseth
Olav
O
Larsson
Henrik B W
HB
Jynge
Per
P
D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000737:chemistry; D003287:Contrast Media / Q000494:pharmacology*; D003331:Coronary Vessels / Q000473:pathology; D004452:Echocardiography / Q000379:methods*; D004492:Edetic Acid / Q000031:analogs & derivatives* / Q000494:pharmacology; D005260:Female; D006352:Heart Ventricles / Q000473:pathology*; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000175:diagnosis* / Q000401:mortality / Q000473:pathology*; D011732:Pyridoxal Phosphate / Q000031:analogs & derivatives* / Q000494:pharmacology; D016896:Treatment Outcome
D015415:Biomarkers; D003287:Contrast Media; D011732:Pyridoxal Phosphate; D004492:Edetic Acid; C060076:N,N'-bis(pyridoxal-5-phosphate)ethylenediamine-N,N'-diacetic acid